Evidence map›Paper›PMID 42303974›Full record

ArticleCell death discovery2026

The IKKα-regulated microRNA miR-9-5p mediates lung cancer growth and invasiveness via CDH1/Wnt/β-catenin signalling.

Simoni Besta, Eugenia Roupakia, Zoi Kanaki, Giannis Vatsellas, Mark Samuels, Spyros Foutadakis, Maria Tokamani, Alessandro Barbon, Raphael Sandaltzopoulos, Dimitris C Kanellis and 6 more

Abstract read
In one paragraph

Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Simoni BestaLaboratory of Biology, School of Medicine, Faculty of Health Sciences, and Institute of Biosciences, Centre for Research and Innovation, University of Ioannina, University Campus, Ioannina, Greece.ORCID http://orcid.org/0009-0000-8185-5083
Eugenia RoupakiaLaboratory of Biology, School of Medicine, Faculty of Health Sciences, and Institute of Biosciences, Centre for Research and Innovation, University of Ioannina, University Campus, Ioannina, Greece.
Zoi KanakiCentre of Basic Research, Biomedical Research Foundation, Academy of Athens, Athens, Greece.
Giannis VatsellasGreek Genome Center, Biomedical Research Foundation, Academy of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-1631-1060
Mark SamuelsDepartment of Biochemistry and Biomedicine, School of Life Sciences, University of Sussex, Brighton, UK.
Spyros Foutadakis4th Department of Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-9161-1605
Maria TokamaniDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Thrace, Greece.
Alessandro BarbonDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Raphael SandaltzopoulosDepartment of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Thrace, Greece.ORCID http://orcid.org/0000-0002-8490-4300
Dimitris C KanellisScience for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-8690-2010
Jiri BartekScience for Life Laboratory, Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-2013-7525
Maria HatziapostolouDepartment of Biosciences, John van Geest Cancer Research Centre, Centre for Systems Health and Integrated Metabolic Research, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
Christos PolytarchouDepartment of Biosciences, John van Geest Cancer Research Centre, Centre for Systems Health and Integrated Metabolic Research, School of Science and Technology, Nottingham Trent University, Nottingham, UK.
Dimitris ThanosCentre of Basic Research, Biomedical Research Foundation, Academy of Athens, Athens, Greece.ORCID http://orcid.org/0000-0003-4288-3027
Apostolos KlinakisCentre of Basic Research, Biomedical Research Foundation, Academy of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-3923-861X
Evangelos KolettasLaboratory of Biology, School of Medicine, Faculty of Health Sciences, and Institute of Biosciences, Centre for Research and Innovation, University of Ioannina, University Campus, Ioannina, Greece. ekoletas@uoi.gr.ORCID http://orcid.org/0000-0002-5820-487X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IKKα is a serine/threonine kinase that acts as a tumour suppressor in non-small cell lung cancer (NSCLC) in an NF-κΒ-independent manner, however, little is known about its downstream signalling pathways. To interrogate the IKKα signalling network in NSCLC, we investigated the impact of IKKα silencing on the miRNA expression profile of NSCLC cells. Nanostring miRNome analysis identified miR-9-5p, a known oncomir, as the top upregulated miRNA upon IKKα depletion. We show that overexpression of miR-9-5p in human lung cancer cells increases cell migration and invasion and promotes epithelial-to-mesenchymal cell transition (EMT) through loss of E-cadherin and activation of the Akt1/β-catenin pathway. In vivo tumour xenograft models show that overexpression of miR-9-5p promotes tumour growth and widespread transcriptomic reprogramming, altering the expression of genes related to EMT, apoptosis and NF-κB signalling. Overall, we show that miR-9-5p acts as an oncogenic effector upon IKKα loss, promoting tumour progression through EMT and Akt-1/GSK-3β/β-catenin pathway activation, leading to increased invasiveness and tumour growth.

Identifiers

PMID42303974
PMCPMC13507200

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.